DIMAZE

Indications

• Acute pain management
• Chronic pain conditions
• Osteoarthritis
• Rheumatoid arthritis
• Post-operative pain

Dosage

Children: Refer to BNF for Children for appropriate paediatric dosing guidelines.

Adults: Refer to BNF for appropriate adult dosing guidelines.

Mechanism of action

Aceturate acts as an analgesic and anti-inflammatory agent. Its mechanism involves the inhibition of the cyclooxygenase (COX) enzymes, leading to a decrease in the synthesis of prostaglandins, which are mediators of pain and inflammation. This results in reduced pain perception and inflammation at the site of action.

Pharmacodynamics

Aceturate exhibits dose-dependent analgesic effects, providing relief from mild to moderate pain. Its anti-inflammatory properties help to reduce swelling and discomfort in conditions like arthritis and musculoskeletal disorders. The onset of action is typically rapid, leading to quick relief of symptoms.

Pharmacokinetics

Aceturate is absorbed after oral administration, with peak plasma concentrations reached within a few hours. It undergoes hepatic metabolism and is excreted primarily via the renal route. The elimination half-life can vary based on individual metabolic factors but is generally within a manageable range for regular dosing.

Pregnancy

No adequate studies are available on the use of aceturate in pregnant women. It should only be used if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised when aceturate is administered to breastfeeding mothers. The excretion of aceturate in human milk is unknown.

Storage

Store at room temperature, away from moisture and heat. Protect from light.

Indications

• African trypanosomiasis (sleeping sickness) caused by Trypanosoma brucei gambiense
• African trypanosomiasis (sleeping sickness) caused by Trypanosoma brucei rhodesiense

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations in paediatric patients.

Adults: Refer to the BNF for specific dosing recommendations in adults.

Mechanism of action

Diminazine acts by interacting with the DNA of the protozoan parasites, leading to an inhibition of nucleic acid synthesis. It is thought to inhibit mitochondrial functions, disrupting the energy metabolism of the parasites and ultimately leading to their death. The exact molecular pathways are not fully elucidated, but it is known to interfere with the parasite's ability to replicate and survive in the host.

Pharmacodynamics

Diminazine exhibits a dose-dependent effect on the parasites, leading to a reduction in parasitemia. The drug's effectiveness is enhanced in the early stages of infection, and resistance may develop with prolonged use. The clinical response is monitored through parasitological assessments and symptom resolution, with treatment typically administered in a controlled healthcare setting.

Pharmacokinetics

Diminazine is administered parenterally and is rapidly distributed in the body. It has a moderate volume of distribution and is metabolized in the liver, with renal excretion of its metabolites. The half-life of diminazine varies, generally ranging from 4 to 10 hours, depending on individual patient factors. Therapeutic drug monitoring may be employed to assess plasma concentrations and ensure efficacy while minimizing toxicity.

Pregnancy

Diminazine should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether diminazine is excreted in human milk. Caution should be exercised when administering to a nursing mother.

Storage

Store in a cool, dry place, protected from light.

Formulations

• {'name': 'Diminazine Aceturate', 'type': 'Injection', 'strength': '100 mg/mL'}